- Home
- EWCZ vs IMAB Comparison
EWCZ vs IMAB Comparison
Compare EWCZ & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- IMAB
- Stock Information
- Founded
- EWCZ 2004
- IMAB 2014
- Country
- EWCZ United States
- IMAB United States
- Employees
- EWCZ N/A
- IMAB N/A
- Industry
- EWCZ Package Goods/Cosmetics
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- IMAB Health Care
- Exchange
- EWCZ Nasdaq
- IMAB Nasdaq
- Market Cap
- EWCZ 239.2M
- IMAB 200.9M
- IPO Year
- EWCZ 2021
- IMAB 2020
- Fundamental
- Price
- EWCZ $4.22
- IMAB $2.62
- Analyst Decision
- EWCZ Buy
- IMAB Strong Buy
- Analyst Count
- EWCZ 7
- IMAB 3
- Target Price
- EWCZ $5.86
- IMAB $6.33
- AVG Volume (30 Days)
- EWCZ 374.4K
- IMAB 2.6M
- Earning Date
- EWCZ 08-13-2025
- IMAB 05-15-2025
- Dividend Yield
- EWCZ N/A
- IMAB N/A
- EPS Growth
- EWCZ N/A
- IMAB N/A
- EPS
- EWCZ 0.21
- IMAB N/A
- Revenue
- EWCZ $216,469,000.00
- IMAB N/A
- Revenue This Year
- EWCZ N/A
- IMAB N/A
- Revenue Next Year
- EWCZ $2.17
- IMAB N/A
- P/E Ratio
- EWCZ $20.54
- IMAB N/A
- Revenue Growth
- EWCZ N/A
- IMAB N/A
- 52 Week Low
- EWCZ $2.72
- IMAB $0.60
- 52 Week High
- EWCZ $9.45
- IMAB $3.44
- Technical
- Relative Strength Index (RSI)
- EWCZ 26.95
- IMAB 63.02
- Support Level
- EWCZ $4.56
- IMAB $1.65
- Resistance Level
- EWCZ $5.16
- IMAB $2.18
- Average True Range (ATR)
- EWCZ 0.20
- IMAB 0.24
- MACD
- EWCZ -0.07
- IMAB 0.01
- Stochastic Oscillator
- EWCZ 1.44
- IMAB 54.19
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).